Dario Blood Glucose Monitoring System

The Dario Blood Glucose Monitoring System provides a method for individuals with diabetes to quantitatively measure their blood glucose levels from capillary whole blood using a glucose oxidase-based amperometric sensor integrated with a mobile application for data display and management. The system has demonstrated accuracy, precision, and usability in accordance with ISO 15197:2003 through various performance evaluations, including studies on hematocrit effects, operating conditions, and potential interferences.

The Dario Blood Glucose Monitoring System is designed for individuals with diabetes to perform self-testing of their blood glucose levels. It quantitatively measures glucose in fresh capillary whole blood samples drawn from the fingertips, aiding in the home monitoring of diabetes control effectiveness. The system comprises the Dario Blood Glucose Meter (which includes an integrated lancing device and is powered via a smart mobile device's audio jack), Dario Glucose Test Strips, Dario Glucose Control Solutions, and the Dario App, which serves as the display component on an Apple iOS smart mobile device. The underlying test principle involves an amperometric measurement: glucose in the blood sample reacts with glucose oxidase on the test strip, generating a small electrical current that the meter measures. An internal algorithm then calculates the blood glucose level, which is displayed on the mobile app within approximately six seconds. The system underwent comprehensive performance evaluations according to ISO 15197:2003 standards. System accuracy studies demonstrated that, compared to a reference method, 100% of individual glucose results were within ±15 mg/dL for concentrations below 75 mg/dL, and 99.6% were within ±20% for concentrations at or above 75 mg/dL. Precision studies yielded a coefficient of variation (CV) of ≤ 4% for glucose concentrations ≥100 mg/dL and a standard deviation (SD) of ≤ 3 mg/dL for concentrations <100 mg/dL. The device showed linearity across a blood glucose measuring range of 20-600 mg/dL (R²=0.998) and was found to be accurate within a hematocrit range of 20% to 60%, operating temperatures of 10-45°C, relative humidity of 10-90%, and altitudes up to 10,000 feet. The required sample volume is 0.3µL. User performance studies confirmed its accuracy when used by lay individuals, and disinfection and interference studies further validated its robustness and identified specific substance limitations.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the long-term stability and reliability of the glucose oxidase enzyme on the test strips under various storage conditions beyond those explicitly tested in the documentation?; How does the Dario system's performance, particularly its mobile application's data management and user interface, compare to other commercially available mobile-connected glucose monitoring systems in longitudinal, real-world patient studies?; What specific software verification and validation methodologies were employed to ensure the robustness, security, and privacy of patient data handled by the Dario mobile application, especially against potential cybersecurity threats?; For the identified interfering substances, what is the potential clinical impact at their maximum 'no significant interference' concentrations, especially for patients with comorbidities or those on multiple medications?; Were any studies conducted to assess the learning curve and ease of use for patient populations with limited technological literacy, such as elderly individuals, and what are the recommended support strategies for these users?